JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Innoviva Inc

Fermé

SecteurSoins de santé

23.01 0.22

Résumé

Variation du prix de l'action

24h

Actuel

Min

22.77

Max

23.31

Chiffres clés

By Trading Economics

Revenu

152M

242M

Ventes

10M

118M

P/E

Moyenne du Secteur

7.079

67.147

Marge bénéficiaire

204.74

Employés

159

EBITDA

100M

208M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+56.18% upside

Dividendes

By Dow Jones

Prochains Résultats

5 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

70M

1.7B

Ouverture précédente

22.79

Clôture précédente

23.01

Sentiment de l'Actualité

By Acuity

20%

80%

61 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Innoviva Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 avr. 2026, 23:53 UTC

Résultats

Naver Posts Weaker First-Quarter Earnings

29 avr. 2026, 23:41 UTC

Actions en Tendance

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 avr. 2026, 23:55 UTC

Résultats

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 avr. 2026, 23:54 UTC

Résultats

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 avr. 2026, 23:52 UTC

Résultats

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 avr. 2026, 23:51 UTC

Résultats

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 avr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 avr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 avr. 2026, 23:24 UTC

Résultats

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 avr. 2026, 23:22 UTC

Résultats

China Longyuan 1Q Net CNY1.70B, Down 14%

29 avr. 2026, 23:22 UTC

Résultats

China Longyuan: Power Generation Down 2.9% as of End-March

29 avr. 2026, 23:20 UTC

Résultats

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 avr. 2026, 23:20 UTC

Résultats

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 avr. 2026, 23:19 UTC

Résultats

China Vanke 1Q Loss Narrows>000002.SZ

29 avr. 2026, 23:18 UTC

Résultats

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 avr. 2026, 23:17 UTC

Résultats

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 avr. 2026, 23:15 UTC

Résultats

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 avr. 2026, 23:15 UTC

Résultats

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 avr. 2026, 23:13 UTC

Résultats

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 avr. 2026, 23:12 UTC

Résultats

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 avr. 2026, 23:11 UTC

Résultats

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 avr. 2026, 23:11 UTC

Résultats

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 avr. 2026, 23:04 UTC

Résultats

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 avr. 2026, 23:04 UTC

Résultats

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparaison

Variation de prix

Innoviva Inc prévision

Objectif de Prix

By TipRanks

56.18% hausse

Prévisions sur 12 Mois

Moyen 37 USD  56.18%

Haut 46 USD

Bas 32 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

18.57 / 18.75Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

61 / 348Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat